Intact Vascular Announces Enrollment Completion of the Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial
WAYNE, PA – April 16, 2018 – Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has completed enrollment. A total of 200 patients have been enrolled in TOBA III at 14 sites in Europe.
The TOBA III study is a prospective, multi-center, single-arm study designed to investigate the safety and efficacy of the Tack Endovascular System® in combination with the Medtronic IN.PACT™ Admiral™ drug-coated balloon (DCB) in the treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. The study includes a cohort of patients with long lesions, which are particularly challenging to treat successfully.
The Tack Endovascular System® is a new solution for precision dissection repair following balloon angioplasty with a first-of-its-kind implant that is designed to help maintain vessel integrity and enhance blood flow to promote healing, improve outcomes and preserve limbs. Unrepaired dissections — which are frequent following balloon angioplasty — increase the probability of acute arterial occlusion and may continue narrowing the artery, which leads to lower long-term patency rates. The Tack Endovascular System leaves a minimal amount of metal in the artery, reduces mechanical stress on the arterial wall and preserves future treatment options.
“Even in the era of drug-eluting technologies, post-angioplasty dissections continue to hinder long-term patency,” commented Professor Dr. Marianne Brodmann, Head of the Clinical Division of Angiology, Medical University Graz, Austria. “ I am encouraged that the Tack Endovascular System may provide durable, focal dissection repair using the least amount of metal and force in the artery.”
“Our mission at Intact Vascular is to make all forms of angioplasty more effective and durable. TOBA III seeks to accomplish that goal with the Medtronic DCB and in particularly challenging lesions,” said Bruce Shook, Intact Vascular’s President and CEO. “We want to thank our European investigators for their commitment to this important project and for completing study enrollment ahead of schedule.”
Intact Vascular is sponsoring two additional clinical trials to evaluate its Tack Endovascular System: TOBA II and TOBA II BTK. TOBA II is investigating the combination of the Tack device with both plain and drug-coated balloon angioplasty in the arteries above the knee, and completed enrollment in March 2017. TOBA II BTK is investigating the combination of the Tack device with plain balloon angioplasty in the arteries below the knee and is actively enrolling patients.
Visit http://www.intactvascular.com/clinical-trials/current-clinical-trials/ for more information on Intact Vascular’s robust clinical development program in the endovascular treatment of peripheral arterial disease and critical limb ischemia.
About Intact Vascular
Intact Vascular is a privately held medical device company that develops minimally- invasive peripheral vascular products. The Tack Endovascular System is designed to improve peripheral balloon angioplasty results in the treatment of peripheral arterial disease. Visit www.intactvascular.com for more information.
This press release contains “forward-looking statements” concerning the development of Intact Vascular’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Intact Vascular undertakes no obligation to update any forward-looking statements for any reason.